iiinova — where your digital self keeps evolving

Reposted by Sherene Loi MD

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 30/05/2025

The chemo-free combo of Ribo+Let+trastuzumab led to mOFS 30.4 months, good ORR, and minimal cardiac toxicity in this ph2 1L Korean study. #ASCO25 @oncoalert.bsky.social

172

Sherene Loi MD @loisher.bsky.social · 30/05/2025

Pleased to be part of these elections!

030

Reposted by Sherene Loi MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 14/05/2025

In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups. Full article in the #ESMODailyReporter 🔗 ow.ly/rtbo50VSyiN

042

Reposted by Sherene Loi MD

The ASCO Post @ascopost.bsky.social · 16/04/2025

Does the timing of neoadjuvant nivolumab initiation affect outcomes in early-stage triple-negative breast cancer? A phase II study led by Dr. Sherene Loi explores this critical question. Read more: ascopost.com/news/march-2... #TripleNegativeBreastCancer #Immunotherapy

ascopost.com

Triple-Negative Breast Cancer: Neoadjuvant Nivolumab Initiation

The phase II Neo-N trial investigated the activity of two differing schedules of neoadjuvant nivolumab initiation—lead-in or concurrent—with 12 weeks of carboplatin and paclitaxel in patients with ear...

031

Reposted by Sherene Loi MD

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 12/03/2025

Dr. Janni reviews ongoing ctDNA trials w/de-escalation, escalation. Starts with historical perspective that attempts to use CT/body imaging for early disease recurrence did NOT improve overall survival, only increased detection of recurrence (lead time bias). #SGBCC2025

041

Sherene Loi MD @loisher.bsky.social · 22/02/2025

@thelancet.bsky.social the Lancet summit for cancer control in China 🇨🇳 Great discussion for #breastcancer #lungcancer #GIcancers

030

Reposted by Sherene Loi MD

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 07/02/2025

Many good things to say on this story @oncoalert.bsky.social @naturemedicine.bsky.social: 1) serious biomarker work from a pharma-sponsored trial👏👏 2) a tumor historically consid cold 🥶can respond to aPD1 🤩3) we need to redefine ER+ disease to enable personalized treatm✍️

032

Sherene Loi MD @loisher.bsky.social · 08/02/2025

🎈our recent collaborative review on “Complexities of Cancer” highlighted here 👏👏👏 🙏 @cp-cell.bsky.social as well as many other seminal articles- well worth a look 👀 @oncoalert.bsky.social

042

Sherene Loi MD @loisher.bsky.social · 05/02/2025

Remembering Jose Baselga and the superstar 👏⭐️ he was

030

Sherene Loi MD @loisher.bsky.social · 31/01/2025

🎈Adjuvant Atezo for fully resected #TNBC #breastcancer is of NO benefit. We’ll see soon results from SWOG trial in re post neoadjuvant (w/o IO). Exposure to antigen and draining LN seems v. important for ICB efficacy. @oncoalert.bsky.social #bcsm

041

Sherene Loi MD @loisher.bsky.social · 22/01/2025

➡️➡️ very exciting news for estrogen receptor + #breastcancer- a subset is very immunogenic - this data changes the way we think about T cell immunosurveillance in this BC subtype 👏👏👏

030

Reposted by Sherene Loi MD

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 19/01/2025

📌 Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges 👉🏻 sciencedirect.com/science/articl… @ilanaschlam.bsky.social @loisher.bsky.social @oncoalert.bsky.social

054

Sherene Loi MD @loisher.bsky.social · 16/01/2025

Looking fwd to the joint annual meeting of 🇯🇵 #jcog #kbcs 🇰🇷#tibcs 🇹🇼 and @BCTrialsANZ 🇦🇺 in #nagoya #breastcancer trials

010

Reposted by Sherene Loi MD

Peter MacCallum Cancer Centre @petermaccc.bsky.social · 03/12/2024

We are incredibly proud to announce that five Peter Mac researchers have been named in Clarivate's top 1% most cited researchers worldwide for 2024. Read more: www.petermac.org/about-us/new...

093

Sherene Loi MD @loisher.bsky.social · 12/12/2024

#sabcs24 HR+HER2+ #breastcancer now finally its own entity 👏👏👏

061

Sherene Loi MD @loisher.bsky.social · 12/12/2024

#sabcs24 State of the Art session speakers Immune bio markers #til thanks to @balkolab @psharmab

150